Clinical Trial Update: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) [Phase 1]

View source ↗

Summary

Phase Ib study of VK-2019 in patients with EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Epstein-barr Virus Infection

Drugs mentioned

• VK 2019 (VK-2019 EBNA1 inhibitor)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | Phase 1 | Status: RECRUITING